1:50 – 5:00 8/30 CONSIDERATIONS IN DESIGNING IMMUNOTHERAPY COMBINATIONS @IMMUNO-ONCOLOGY SUMMIT – AUGUST 30-31, 2016 | Marriott Long Wharf Hotel – Boston, MA
Leaders in Pharmaceutical Business intelligence (LPBI) Group covers in Real Time the IMMUNO-ONCOLOGY SUMMIT using Social Media
Founder, LPBI Group & Editor-in-Chief
http://pharmaceuticalintelligence.com
I attended a parallel session @ Marriott Long Wharf Hotel in Boston
Curation of Scientific Content @Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston
1:50 – 5:00 8/30 CONSIDERATIONS IN DESIGNING IMMUNOTHERAPY COMBINATIONS
1:50 Rational Combination Immunotherapy Development Stratified by the Presence or Absence of the T Cell-Inflamed Tumor Microenvironment
Jason J. Luke, M.D., FACP, Assistant Professor, Medicine, Melanoma and Developmental Therapeutics Clinics, University of Chicago Medical Center Tumors can be categorized by gene expression based on the presence or absence of a T cell-inflamed tumor microenvironment, and this correlates with either response or lack of response to immune-checkpoint blockade. Categorization of these biologically distinct subsets suggests rational immunotherapy combinations directed toward either a T cell-inflamed or non-T cell-inflamed tumor microenvironment. This approach also facilitates a framework for interrogating molecular mechanism of immune exclusion mediating non-inflamed tumors.
2:20 Programming DCs in situ for Cancer Vaccination
Omar Ali, Ph.D., Staff Scientist, Wyss Institute for Biologically Inspired Engineering, Harvard University The innate components required to mediate effective vaccination against weak tumor-associated antigens remain unclear. We utilize three-dimensional and macroporous, polymeric cancer vaccines incorporating different classes of TLR adjuvants to induce tumor regression and protection in order to identify dendritic cell subsets and cytokines critical to this efficacy. Vaccine-induced tumor regression correlated to local CD8(+) DC and pDC numbers, IL-12, and G-CSF concentrations regardless of the incorporated adjuvant.
2:50 Sponsored Presentations (Opportunities Available)
3:20 Refreshment Break in the Exhibit Hall with Poster Viewing
4:00 PLENARY KEYNOTE SESSION See Keynotes for details.
4:00 A New Era of Personalized Therapy: Using Tumor Neoantigens to Unlock the Immune System
Matthew J. Goldstein, M.D., Ph.D., Director, Translational Medicine, Neon Therapeutics, Inc. Neon Therapeutics, Inc. launched in 2015 to focus on advancing neoantigen biology to improve cancer patient care. A neoantigen-based product engine will allow Neon to develop further treatment modalities including next-generation vaccines and T cell therapies targeting both personalized as well as shared neoantigens. The company’s first trial will launch later this year investigating the combination of a personalized, vaccine with nivolumab in advanced Melanoma, NSCLC, and Bladder Cancer.
4:30 Emerging Innate Immune Targets for Enhancing Adaptive Anti-Tumor Responses
Michael Rosenzweig, Ph.D., Executive Director, Biology-Discovery, IMR Early Discovery, Merck Research Laboratories Novel cancer immunotherapies targeting T cell checkpoint proteins have emerged as powerful tools to induce profound, durable regression and remission of many types of cancer. Despite these advances, multiple studies have demonstrated that not all patients respond to these therapies, and the ability to predict which patients may respond is limited. Harnessing the innate immune system to augment the adaptive anti-tumor response represents an attractive target for therapy, which has the potential to enhance both the percentage and rate of response to checkpoint blockade.
5:00 Reading Tea Leaves: The Dilemma of Prediction and Prognosis in Immunotherapy
Morganna Freeman, D.O., Associate Director, Melanoma & Cutaneous Oncology Program, The Angeles Clinic and Research Institute With the rapid expansion of immunotherapeutics in oncology, scientifically significant advances have been made with both the depth and duration of antitumor responses. However, not all patients benefit, or quickly relapse, thus much scientific inquiry has been devoted to appropriate patient selection and how such obstacles might be overcome. While more is known about potential biomarkers, accurate prognostication persists as a knowledge gap, and efforts to bridge it will be discussed here.
Leave a Reply